Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).

Selective androgen receptor modulators (SARMs) are a novel class of androgen receptor (AR) ligands that might change the future of androgen therapy dramatically. With improved pharmacokinetic characteristics and tissue-selective pharmacological activities, SARMs are expected to greatly extend the clinical applications of androgens to osteoporosis, muscle wasting, male contraception and diseases of the prostate. Mechanistic studies with currently available SARMs will help to define the contributions of differential tissue distribution, tissue-specific expression of 5alpha-reductase, ligand-specific regulation of gene expression and AR interactions with tissue-specific coactivators to their observed tissue selectivity, and lead to even greater expansion of selective anabolic therapies.

[1]  Shihua Sun,et al.  Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.

[2]  M. Oettel.  Testosterone metabolism, dose–response relationships and receptor polymorphisms: selected pharmacological/toxicological considerations on benefits versus risks of testosterone therapy in men , 2003, The aging male : the official journal of the International Society for the Study of the Aging Male.

[3]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[4]  R. Rittmaster,et al.  Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5α-Reductase1. , 1999, Endocrinology.

[5]  Duane D. Miller,et al.  Pharmacodynamics of Selective Androgen Receptor Modulators , 2003, Journal of Pharmacology and Experimental Therapeutics.

[6]  Duane D. Miller,et al.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Kurth,et al.  Placebo Controlled Double-blind Study to Test the Efficacy of the Aromatase Inhibitor Atamestane in Patients with Benign Prostatic Hyperplasia not Requiring Operation , 1995 .

[8]  E. Barrett-Connor,et al.  Endogenous sex hormones and cognitive function in older men. , 1999, The Journal of clinical endocrinology and metabolism.

[9]  Seiji Amano,et al.  Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. , 2003, Biological & pharmaceutical bulletin.

[10]  B. Katzenellenbogen,et al.  Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors Dissociation from Transcriptional Activity , 2001, Cell.

[11]  T. Saibara,et al.  Oestrogen at the neonatal stage is critical for the reproductive ability of male mice as revealed by supplementation with 17beta-oestradiol to aromatase gene (Cyp19) knockout mice. , 2001, The Journal of endocrinology.

[12]  W. Pratt,et al.  Steroid receptor interactions with heat shock protein and immunophilin chaperones. , 1997, Endocrine reviews.

[13]  D. Colombo,et al.  A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  D. McDonnell,et al.  Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. , 2005, Molecular endocrinology.

[15]  R. Fletterick,et al.  Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators* , 2005, Journal of Biological Chemistry.

[16]  Duane D. Miller,et al.  Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. , 2005, Endocrinology.

[17]  E. Orwoll.  Men, bone and estrogen: unresolved issues , 2003, Osteoporosis International.

[18]  Manuel Estrada,et al.  Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. , 2003, Endocrinology.

[19]  M. Monga,et al.  Medical management of benign prostatic hyperplasia. , 1999, Geriatric nephrology and urology.

[20]  S. Balk,et al.  The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists* , 2005, Journal of Biological Chemistry.

[21]  M. A. Carrondo,et al.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. , 2000, The Journal of biological chemistry.

[22]  Y. Shang,et al.  Formation of the androgen receptor transcription complex. , 2002, Molecular cell.

[23]  K. Kurth,et al.  Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. , 1995, The Journal of urology.

[24]  S. Hammes,et al.  Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands. , 2003, Molecular endocrinology.

[25]  H. Tucker,et al.  The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. , 1996, Urology.

[26]  J. Morley,et al.  Biological actions of androgens. , 1987, Endocrine reviews.

[27]  Duane D. Miller,et al.  A Selective Androgen Receptor Modulator for Hormonal Male Contraception , 2005, Journal of Pharmacology and Experimental Therapeutics.

[28]  Anthony W. Norman,et al.  Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model , 2004, Nature Reviews Drug Discovery.

[29]  A. Eckardstein,et al.  Testosterone and atherosclerosis. , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[30]  W. Foye,et al.  Foye's Principles of Medicinal Chemistry , 2002 .

[31]  L. Björnström,et al.  Estrogen receptor-dependent activation of AP-1 via non-genomic signalling , 2004, Nuclear receptor.

[32]  Chawnshang Chang,et al.  The androgen receptor: a mediator of diverse responses. , 1996, Frontiers in bioscience : a journal and virtual library.

[33]  R. Buijsman,et al.  Non-steroidal steroid receptor modulators. , 2005, Current medicinal chemistry.

[34]  T. Senge,et al.  Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  Ephraim E. Parent,et al.  Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide. , 2006, Nuclear medicine and biology.

[36]  J. Katzenellenbogen,et al.  A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labeled androgens in the rat. , 1990, Journal of steroid biochemistry.

[37]  M. S. Fletcher,et al.  Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: Results of a double‐blind, placebo‐controlled, randomized clinical trial using two doses of the aromatase‐inhibitor atamestane , 1996, The Prostate.

[38]  Duane D. Miller,et al.  Discovery of nonsteroidal androgens. , 1998, Biochemical and biophysical research communications.

[39]  M. Wolff,et al.  BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY , 1996 .

[40]  A. von Eckardstein,et al.  Androgens and coronary artery disease. , 2003, Endocrine reviews.

[41]  A. Bilancio,et al.  Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation , 2000, The EMBO journal.

[42]  H. Pols,et al.  The importance of oestrogens in males , 2003, Clinical endocrinology.

[43]  M. Oettel.  Is there a role for estrogens in the maintenance of men's health? , 2002, The aging male : the official journal of the International Society for the Study of the Aging Male.

[44]  Peter Scholz,et al.  Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.

[45]  A. Parfitt,et al.  Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids , 2002, Science.

[46]  Russell Turner,et al.  An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. , 2007, Endocrinology.

[47]  Kozo Nakamura,et al.  Suppressive function of androgen receptor in bone resorption , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Segal,et al.  Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery , 2006, Expert opinion on investigational drugs.

[49]  R. Eastell,et al.  Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. , 2000, The Journal of clinical investigation.

[50]  J. Dalton,et al.  Chemistry and structural biology of androgen receptor. , 2005, Chemical reviews.

[51]  A. Negro-Vilar.  Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. , 1999, The Journal of clinical endocrinology and metabolism.

[52]  J. Dalton,et al.  Discovery and therapeutic promise of selective androgen receptor modulators. , 2005, Molecular interventions.

[53]  U. Francke,et al.  Molecular genetics of steroid 5 alpha-reductase 2 deficiency. , 1992, The Journal of clinical investigation.

[54]  Weida Tong,et al.  Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. , 2003, Chemical research in toxicology.

[55]  Y. Zagar,et al.  Signaling Cross-talk from Gβ4 Subunit to Elk-1 in the Rapid Action of Androgens* , 2004, Journal of Biological Chemistry.

[56]  R. Cadilla,et al.  Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. , 2006, Current topics in medicinal chemistry.

[57]  C. Heinlein,et al.  Androgen receptor (AR) coregulators: an overview. , 2002, Endocrine reviews.

[58]  J. Dalton,et al.  Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands , 2006, Pharmaceutical Research.

[59]  J. Edwards,et al.  New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. , 1998, Bioorganic & medicinal chemistry letters.

[60]  Duane D. Miller,et al.  Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. , 2004, Endocrinology.

[61]  F. Claessens,et al.  Interplay between two hormone-independent activation domains in the androgen receptor. , 2006, Cancer research.

[62]  I. Cockshott.  Bicalutamide: clinical pharmacokinetics and metabolism. , 2004, Clinical pharmacokinetics.

[63]  D. Kazmin,et al.  Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. , 2003, Cancer research.

[64]  J. Kaufman,et al.  Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. , 2003, Atherosclerosis.

[65]  D. Russell,et al.  The Molecular Genetics of Steroid 5α-Reductases , 1994 .

[66]  C. Stournaras,et al.  The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors, which increase PSA secretion and modify actin cytoskeleton , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  T. Mukherjee,et al.  Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: Implications in atherosclerosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.